Sector Experts

Mara Goldstein

Cantor Fitzgerald

Image: Mara Goldstein

Mara Goldstein joined Cantor Fitzgerald & Co. from Thomson Reuters, where she served as director of research for Reuters Insight. Goldstein was initially responsible for the firm's healthcare research practice, and later assumed responsibility for all research activities and sectors. Prior to that, Goldstein was an executive director and senior pharmaceutical analyst at CIBC World Markets. At Cantor, Goldstein covers the biotechnology sector. Goldstein also worked at Alex Brown & Sons and CS First Boston. She holds a bachelor's degree in economics from Purdue University.




Recent Interviews

Watchlist Analysts Forecast Continued Blue Sky for Biotech Industry (1/29/15) For the last two years the biotech sector has experienced market-beating gains, even taking into account the industry-wide hiccup in early 2014. Can this trend continue? The five analysts who selected names for The Life Sciences Report's 2015 Small-Cap Biotech Watchlist spend their days considering this question; it comes into play with every recommendation they make. The topic came up in various contexts during the Watchlist panel at the 2015 Biotech Showcase: Here are four factors investors should consider as they move into 2015.

The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here? (1/27/15) At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and found every reason to believe its good health would continue into 2015 and beyond. The experts also sent investors who attended the panel discussion of The Life Sciences Report's 2015 Small-Cap Biotech Watchlist home with a bundle of robust investment opportunities, including a few new names. Read on to see which companies made the list, and why.

2015 Small-Cap Biotech Watchlist Announced (12/18/14) In its third year, The Life Sciences Report's 2015 Small-Cap Biotech Watchlist currently includes 12 drug development companies selected by leading analysts in the sector. With catalysts on the horizon and pipelines that encompass a variety of indications and innovative platforms, these biotechs are primed to return multiples on investment.

Recent Quotes

"SNSS' pipeline compounds have the ability to expand share valuation." (7/30/15) Sunesis Pharmaceuticals Inc. - Mara Goldstein, Cantor Fitzgerald More >

"We believe that SNSS will file a new drug application for Qinprezo." (6/12/15) Sunesis Pharmaceuticals Inc. - Mara Goldstein, Cantor Fitzgerald More >

"SNSS will submit an NDA for Qinprezo for AML, later this year." (5/14/15) Sunesis Pharmaceuticals Inc. - Mara Goldstein, Cantor Fitzgerald More >

"We think SNSS's next inflection point will be confirmation of NDA filing in the U.S." (3/13/15) Sunesis Pharmaceuticals Inc. - Mara Goldstein, Cantor Fitzgerald More >

"There is opportunity for the FDA to accept a new drug application filing from SNSS." (1/27/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with Mara Goldstein More >

"We believe the FDA will agree to review SNSS' NDA filing, resulting in a revalued share price." (1/6/15) Sunesis Pharmaceuticals Inc. - Mara Goldstein, Cantor Fitzgerald More >

"We are upgrading SNSS to a Buy." (12/10/14) Sunesis Pharmaceuticals Inc. - Mara Goldstein, Cantor Fitzgerald More >

"GALE's E39 is in early development for ovarian and endometrial cancers that overexpress folate-binding protein, an interesting target." (8/1/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Mara Goldstein More >



Due to permission requirements, not all quotes are shown.